Introduction Timely initiation of anti-HER2 therapy is crucial for improving outcomes in patients with HER2-positive early breast cancer. In low- and middle-income countries (LMICs), health-system constraints—ranging from diagnostic delays to limited access to targeted therapies—can hinder timely treatment. This retrospective cohort study examines whether a structured Patient Navigation Program can streamline care, reduce delays, and…